Tae Min Kim

Research interests

Publications

• Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.01725

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002787

• Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00457

• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30339-x

• Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30146-2

• Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00077-2

Current projects

No projects listed.